It is estimated that up to 14% of patients with HIV have diabetes mellitus (DM), which
is a determinant risk factor for the development of cardiovascular disease [
[1]
]. The therapeutic regimen is the same as that recommended in clinical practice guidelines
such as the American Diabetes Association (ADA) and the European Diabetes Association
(EASD) [
[2]
].Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- The prevalence and pathogenesis of diabetes mellitus in treated HIV-infection.Best Pract Res Clin Endocrinol Metab. 2011; 25: 469-478
- Standards of medical care in diabetes—2016.Diabetes Care. 2016; 39
- Sodium glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis.Ann Intern Med. 2013; 159: 262-274
- Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.Drug Des Devel Ther. 2014; 11: 1335-1380
- Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.Curr Med Res Opin. 2016; 32: 1087-1096
Article info
Publication history
Published online: March 18, 2017
Accepted:
March 2,
2017
Received in revised form:
March 1,
2017
Received:
February 26,
2017
Identification
Copyright
© 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
